The herpes zoster vaccine (Zostavax) has been shown to decrease the risk of shingles by almost 70 percent. The vaccine has been shown to be effective and is approved by the Food and Drug Administration for adults age 50 and older and is recommended for all adults 60 and older regardless of whether they have had shingles in the past.
Nov. 13, 2012
- Treatment of postherpetic neuralgia. American Academy of Neurology. http://www.aan.com/professionals/practice/pdfs/pn_guideline_patients.pdf. Accessed July 3, 2012.
- Bajwa ZH, et al. Postherpetic neuralgia. http://www.uptodate.com/home/index.html. Accessed July 3, 2012.
- Watson P. Postherpetic neuralgia. American Family Physician. 2011;84:690.
- Habif TP. Clinical Dermatology: A Color Guide to Diagnosis and Therapy. 5th ed. Edinburgh, U.K.; New York, N.Y.: Mosby Elsevier; 2010. http://www.mdconsult.com/books/about.do?about=true&eid=4-u1.0-B978-0-7234-3541-9..X0001-6--TOP&isbn=978-0-7234-3541-9&uniqId=230100505-57. Accessed July 3, 2012.
- Ultram (tramadol hydrochloride), Ultracet (tramadol hydrochloride/acetaminophen): Label change. U.S. Food and Drug Administration. http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm213264.htm. Accessed July 3, 2012.
- Watson JC (expert opinion). Mayo Clinic, Rochester, Minn. July 17, 2012.
- Irving GA, et al. NGX-4010, a capsaicin 8% dermal patch, administered alone or in combination with systemic neuropathic pain medications, reduces pain in patients with postherpetic neuralgia. Clinical Journal of Pain. 2012;28:101.
- Centers for Disease Control and Prevention, et al. Update on herpes zoster vaccine: Licensure for persons aged 50 through 59 years. MMWR. 2011;60:44. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6044a5.htm?s_cid=mm6044a5_w. Accessed July 18, 2012.